Atopic dermatitis is a systemic inflammatory disorder where both innate immune cells such as dendritic cells (DCs) and adaptive immune cells, such as B and T cells, contribute to cutaneous ...

After more than a decade without any therapeutic advancements in chronic obstructive pulmonary disorder (COPD), people with ...

Senior Market Sales® (SMS), one of the nation's premier insurance marketing organizations, has made a key addition to its ...

J.P. Morgan analyst Chris Schott has maintained their neutral stance on AMGN stock, giving a Hold rating today. Chris Schott has given his ...

New proteomic analyses show that rezpegaldesleukin increases the protein levels of immune-regulating pathways while reducing specific serum proteins known to be elevated in patients with atopic ...

Amgen said on Tuesday that its drug helped improve daily activities including chewing and swallowing in patients suffering from a rare muscle-weakening disease, meeting the main goal of a late-stage ...

Our assumed 2031 GLP-1 penetration rates are ahead of advanced drug penetration in psoriasis and atopic dermatitis, but the ...

Tarsus Pharmaceuticals is expanding its pipeline to target meibomian gland disease and rosacea, with promising Phase 2 ...

This week, the FDA approved Eli Lilly’s LLY eczema drug, Ebglyss (lebrikizumab), and the expanded use of Novartis’ NVS ...

The U.S. Food and Drug Administration has approved Elanco Animal Health's skin disease treatment for dogs, the health ...

Before the FDA approved AstraZeneca’s Fasenra, Nucala was the only therapy for treating eosinophilic granulomatosis with ...

The Phase III trial compared the efficacy of Fasenra with the standard treatment of GSK’s Nucala in patients with ...